Recently, three studies in Chinese GC cases applied the same FDA-approved reagents and scoring criteria and reported HER2 IHC 3+ rates of 9.0% (77/860) [25], 6.9% (10/145) [26], and 5.8% (4/69) [27], respectively, all slightly lower than the present result. The gene discussed is ERBB2; the disease is gastric cancer.